Search Results

You are looking at 41 - 50 of 807 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Matthew G. Ewend, David E. Morris, Lisa A. Carey, Alim M. Ladha, and Steven Brem

metastases. Histology, multiplicity, surgery, and survival . Cancer 1996 ; 78 : 1781 – 1788 . 2. Patchell RA Tibbs PA Regine WF . Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial . JAMA 1998

Full access

Nathan Y. Yu, Terence T. Sio, Vinicius Ernani, Panayiotis Savvides, and Steven E. Schild

SCLC has one of the highest propensities to spread to the brain. 1 With as many as three-quarters of patients developing brain metastases during their disease course, reducing the risk of central nervous system (CNS) failure appears important. 2

Full access

Stephen B. Edge and David G. Sheldon

. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures . Cancer 1982 ; 50 : 1309 – 1314 . 17 Silverstein MJ Lagios MD Martino S . Outcome after

Full access

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

revealed recurrent diffuse omental metastases. She was then restarted on erlotinib and bevacizumab, with prompt resolution of her ascites and abdominal discomfort. Bevacizumab was subsequently held a month after retreatment because of hypertension and chest

Full access

Nicolas Batty, Naveen Yarlagadda, and Roberto Pili

metastases and an irregular tumor protruding into the bladder lumen with bilateral pelvic lymphadenopathy. ADT was initiated with leuprolide, 30 mg, subcutaneously, and bicalutamide, 50 mg, orally daily. A biochemical response occurred, with a nadir PSA of 6

Full access

Joshua K. Sabari, John V. Heymach, and Beth Sandy

with central nervous system metastases. Rates of grade ≥3 adverse events were lower in patients treated with osimertinib versus platinum-pemetrexed chemotherapy. The phase III, double-blind FLAURA trial of osimertinib randomized 556 patients with

Full access

Takashi Taketa, Kazuki Sudo, Arlene M. Correa, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, Maria-Claudia Campagna, Mariela A. Blum, Heath D. Skinner, Ritsuko U. Komaki, Jeffrey H. Lee, Manoop S. Bhutani, Brian R. Weston, David C. Rice, Stephen G. Swisher, Dipen M. Maru, Wayne L. Hofstetter, and Jaffer A. Ajani

patients had clinical stage II (39.0%) or III (51.7%) cancer. Of the 518 patients, 25 (4.8%) had M1a (celiac lymph node metastases) and were designated clinical stage IVa according to the AJCC 6th edition. 17 Type of Surgery Most of the patients (70

Full access

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Patrick Yung Wen, Nicole R. McMillian, and Maria Ho

. Participation in clinical trials is especially encouraged. Overview Metastases to the brain are the most common intracranial tumors in adults and may occur up to 10 times more frequently than primary brain tumors. Population-based data reported that

Full access

Hans F. Schoellhammer, Gagandeep Singh, and Lucille Leong

Presentation A 48-year-old man presented to City of Hope Comprehensive Cancer Center (COHCC) with a diagnosis of rectal adenocarcinoma and synchronous liver metastases. For 1 year, the patient had been experiencing intermittent hematochezia, thinning stool

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak

metastases given androgen deprivation therapy . J Urol 2002 ; 167 : 2361 – 2367 ; discussion 2367 . 133 Smith MR McGovern FJ Zietman AL . Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for